Abstract
Multiple sclerosis (MS) is thought to be an autoimmune disease in which an unknown trigger initiates an immune response against brain proteins. This autoaggressive response causes the breakdown of the myelin sheaths that protect nerve axons, leading to impaired nerve conduction and subsequent neurodegeneration that are characteristic of MS. Many studies have attempted to determine the exact target within the brain. However, there appear to be multiple targets, which may change over time. No single study has examined all targets nor looked at how they can change over the course of the disease and whether these changes are related to the course of disease. We have approached this by using the single-cell resolution capability of the enzyme-linked immunospot assay to examine cytokine reactivity in MS patients in response to a very large set of overlapping peptides that span the two major proteins of myelin: myelin basic protein and proteolipid protein. Our goal was to use the enzyme-linked immunospot assay to perform comprehensive epitope mapping in relapsing-remitting MS patients in a longitudinal study to help define the role of myelin responses in disease progression.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Raine C. S., and Scheinberg L. C. (1988) On the immunopathology of plaque development and repair in multiple sclerosis. J. Neuroimmunol. 20, 189–201.
Martin R., McFarland H. F., and McFarlin D. E. (1992) Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 10, 153–187.
Allegretta M., Nicklas J. A., Sriram S., and Albertini R. J. (1990) T-cells responsive to myelin basic protein in patients with multiple sclerosis. Science 247, 718–721.
Johnson D., Hafler D. A., Fallis R. J., Lees M. B., Brady R. O., Quarles R. H., and Weiner H. L. (1986) Cell-mediated immunity to myelin-associated glycoprotein, proteolipid protein, and myelin basic protein in multiple sclerosis. J. Neuroimmunol. 13, 99–108.
Kerlero d. R., Hoffman M., Mendel I., Yust I., Kaye J., Bakimer R., et al., (1997) Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions. Eur. J. Immunol. 27, 3059–3069.
Lehmann P. V., Forsthuber T., Miller A., and Sercarz E. E. (1992) Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 358, 155–157.
Tuohy V. K., Yu M., Weinstock-Guttman B., and Kinkel R. P. (1997) Diversity and plasticity of self recognition during the development of multiple sclerosis. J. Clin. Invest 99, 1682–1690.
Vanderlugt C. J., and Miller S. D. (1996) Epitope spreading. Curr. Opin. Immunol. 8, 831–836.
Helms T., Boehm B. O., Asaad R. J., Trezza R. P., Lehmann P. V., and Tary-Lehmann M. (2000) Direct visualization of cytokine-producing recall antigen-specific CD4 memory T-cells in healthy individuals and HIV patients. J. Immunol. 164, 3723–3732.
Adorini L., Muller S., Cardinaux F., Lehmann P. V., Falcioni F., and Nagy Z. A. (1988) in vivo competition between self peptides and foreign antigens in T-cell activation. Nature 334, 623–625.
Tuohy V. K., Yu M., Yin L., Kawczak J. A., and Kinkel R. P. (1999) Spontaneous regression of primary autoreactivity during chronic progression of experimental autoimmune encephalomyelitis and multiple sclerosis. J. Exp. Med. 189, 1033–1042.
Pelfrey C. M., Trotter J. L., Tranquill L. R., and McFarland H. F. (1993) Identification of a novel T-cell epitope of human proteolipid protein (residues 4060) recognized by proliferative and cytolytic CD4+ T-cells from multiple sclerosis patients. J. Neuroimmunol. 46, 33–42.
Pelfrey C. M., Trotter J. L., Tranquill L. R., and McFarland H. F. (1994) Identification of a second T-cell epitope of human proteolipid protein (residues 89106) recognized by proliferative and cytolytic CD4+ T-cells from multiple sclerosis patients. J. Neuroimmunol. 53, 153–161.
Calabresi P. A., Fields N. S., Farnon E. C., Frank J. A., Bash C. N., Kawanashi T., et al. (1998) ELI-spot of Th-1 cytokine secreting PBMC’s in multiple sclerosis: correlation with MRI lesions. J. Neuroimmunol. 85, 212–219.
Pender M. P., Csurhes P. A., Greer J. M., Mowat P. D., Henderson R. D., Cameron K. D., et al. 2000. Surges of increased T-cell reactivity to an encephalitogenic region of myelin proteolipid protein occur more often in patients with multiple sclerosis than in healthy subjects. J. Immunol. 165, 5322–5331.
Hellings N., Gelin G., Medaer R., Bruckers L., Palmers Y., Raus J., et al. (2002) Longitudinal study of antimyelin T-cell reactivity in relapsing-remitting multiple sclerosis: association with clinical and MRI activity. J. Neuroimmunol. 126, 143–160.
Arbour N., Holz A., Sipe J. C., Naniche D., Romine J. S., Zyroff J., et al. (2003) A new approach for evaluating antigen-specific T-cell responses to myelin antigens during the course of multiple sclerosis. J. Neuroimmunol. 137, 197–209.
Olsson T., Zhi W. W., Hojeberg B., Kostulas V., Jiang Y. P., Anderson G., et al (1990) Autoreactive T-lymphocytes in multiple sclerosis determined by antigeninduced secretion of interferon-gamma. J. Clin. Invest 86, 981–985.
Rudick R. A., Cutter G., Baier M., Fisher E., Dougherty D., Weinstock-Guttman B., et al. (2001) Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS. Neurology 56, 1324–1330.
Fisher E., Rudick R. A., Cutter G., Baier M., Miller D., Weinstock-Guttman B., et al. (2000) Relationship between brain atrophy and disability: an 8-year followup study of multiple sclerosis patients. Mult. Scler. 6, 373–377.
Rudick R. A., Fisher E., Lee J. C., Duda J. T., and Simon J. (2000) Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a. Mult. Scler. 6, 365–372.
Rudick R. A., Fisher E., Lee J. C., Simon J., and Jacobs L. (1999) Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 53, 1698–1704.
Pelfrey C. M., Rudick R. A., Cotleur A. C., Lee J. C., Tary-Lehmann M., and Lehmann P. V. (2000) Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production. J. Immunol. 165, 1641–1651.
Pelfrey C. M., Cotleur A. C., Lee J. C., and Rudick R. A. (2002) Sex differences in cytokine responses to myelin peptides in multiple sclerosis. J. Neuroimmunol. 130, 211–223.
Moldovan I. R., Rudick R A., Cotleur A. C., Born S., Lee J. C., Karafa M., and Pelfrey C. M. 2003. Interferon gamma responses to myelin peptides in multiple sclerosis correlate with a new clinical measure of disease progression. J. Neuroimmunol. 141, 132–140.
Elliott E. A., McFarland H. I., Nye S. H., Cofiell R., Wilson T. M. Wilkins J. A., et al. 1996. Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein. J. Clin. Invest 98, 1602–1612.
Nye S. H., Pelfrey C. M., Burkwit J. J., Voskuhl R. R., Lenardo M. J., and Mueller J. P. (1995) Purification of immunologically active recombinant 21.5 kDa isoform of human myelin basic protein. Mol. Immunol. 32, 1131–1141.
Kreher C. R., Dittrich M. T., Guerkov R., Boehm B. O., and Tary-Lehmann M. (2003) CD4+ and CD8+ cells in cryopreserved human PBMC maintain full functionality in cytokine ELISPOT assays. J. Immunol. Methods 278, 79–93.
Mishell B. B., and Shiigi S. M. (eds.) Selected Methods in Cellular Immunology. W.H. Freeman and Company, New York, p. 23.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Pelfrey, C.M., Moldovan, I.R. (2005). Epitope Mapping in Multiple Sclerosis Using the ELISPOT Assay. In: Kalyuzhny, A.E. (eds) Handbook of ELISPOT. Methods in Molecular Biology™, vol 302. Humana Press. https://doi.org/10.1385/1-59259-903-6:219
Download citation
DOI: https://doi.org/10.1385/1-59259-903-6:219
Publisher Name: Humana Press
Print ISBN: 978-1-58829-469-2
Online ISBN: 978-1-59259-903-5
eBook Packages: Springer Protocols